Obesity and metabolic syndrome as related to cardiovascular disease

References

• Duvnjak L, Duvnjak M. The metabolic syndrome – an ongoing story. J. Physiol. Pharmacol. 60(Suppl. 7), 19–24 (2009).
   PubMed Web of Science ®Google Scholar
• Kassi E, Pervanidou P, Kaltsas G, Chrousos G. Metabolic syndrome: definitions and controversies. BMC Med. 9, 48 (2011).
   PubMed Web of Science ®Google Scholar
• Musunuru K. Atherogenic dyslipidemia: cardiovascular risk and dietary intervention. Lipids 45(10), 907–914 (2010).
   PubMed Web of Science ®Google Scholar
• Alberti KG, Eckel RH, Grundy SM et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 120(16), 1640–1645 (2009).
   PubMed Web of Science ®Google Scholar
• Ness-Abramof R, Apovian CM. Waist circumference measurement in clinical practice. Nutr. Clin. Pract. 23(4), 397–404 (2008).
   PubMed Web of Science ®Google Scholar
• Zalesin KC, Franklin BA, Miller WM, Peterson ED, McCullough PA. Impact of obesity on cardiovascular disease. Med. Clin. North Am. 95(5), 919–937 (2011).
   PubMedGoogle Scholar
• Pitocco D, Zaccardi F, Di Stasio E et al. Oxidative stress, nitric oxide, and diabetes. Rev. Diabet. Stud. 7(1), 15–25 (2010).
   PubMedGoogle Scholar
• Bruce KD, Hanson MA. The developmental origins, mechanisms, and implications of metabolic syndrome. J. Nutr. 140(3), 648–652 (2010).
   PubMed Web of Science ®Google Scholar
• Shirai K. Obesity as the core of the metabolic syndrome and the management of coronary heart disease. Curr. Med. Res. Opin. 20(3), 295–304 (2004).
   PubMed Web of Science ®Google Scholar
• Kadoglou NP, Vrabas IS, Kapelouzou A et al. Impact of atorvastatin on serum vaspin levels in hypercholesterolemic patients with moderate cardiovascular risk. Regul. Pept. 170(1–3), 57–61 (2011).
   Google Scholar
• Baer PC. Adipose-derived stem cells and their potential to differentiate into the epithelial lineage. Stem Cells Dev. 20(10), 1805–1816 (2011).
   PubMed Web of Science ®Google Scholar
• Snel M, Sleddering MA, Pijl H et al. The effect of dietary phytosphingosine on cholesterol levels and insulin sensitivity in subjects with the metabolic syndrome. Eur. J. Clin. Nutr. 64(4), 419–423 (2010).
   Google Scholar
• Gustafson B. Adipose tissue, inflammation and atherosclerosis. J. Atheroscler. Thromb. 17(4), 332–341 (2010).
   PubMed Web of Science ®Google Scholar
• Ritchie SA, Connell JM. The link between abdominal obesity, metabolic syndrome and cardiovascular disease. Nutr. Metab. Cardiovasc. Dis. 17(4), 319–326 (2007).
   PubMed Web of Science ®Google Scholar
• Sowers JR, Frohlich ED. Insulin and insulin resistance: impact on blood pressure and cardiovascular disease. Med. Clin. North Am. 88(1), 63–82 (2004).
   PubMed Web of Science ®Google Scholar
• Nieto-Vazquez I, Fernández-Veledo S, Krämer DK, Vila-Bedmar R, Garcia-Guerra L, Lorenzo M. Insulin resistance associated to obesity: the link TNF-alpha. Arch. Physiol. Biochem. 114(3), 183–194 (2008).
   PubMedGoogle Scholar
• Boura-Halfon S, Zick Y. Serine kinases of insulin receptor substrate proteins. Vitam. Horm. 80, 313–349 (2009).
   PubMed Web of Science ®Google Scholar
• Schulman IH, Zhou MS. Vascular insulin resistance: a potential link between cardiovascular and metabolic diseases. Curr. Hypertens. Rep. 11(1), 48–55 (2009).
   PubMed Web of Science ®Google Scholar
• Kirk EP, Klein S. Pathogenesis and pathophysiology of the cardiometabolic syndrome. J. Clin. Hypertens. (Greenwich) 11(12), 761–765 (2009).
   PubMed Web of Science ®Google Scholar
• Bruce KD, Hanson MA. The developmental origins, mechanisms, and implications of metabolic syndrome. J. Nutr. 140, 648–652 (2010).
   PubMed Web of Science ®Google Scholar
• Flakoll PJ, Jensen MD, Cherrington AD. Physiological action of insulin. In: Diabetes Mellitus: A Fundamental and Clinical Text. LeRoith D, Taylor SI, Olefasky JM (Eds). Lippincott, Williams and Wilkins, PA, USA, 165–181 (2004).
   Google Scholar
• Santilli F, Vazzana N, Liani R, Guagnano MT, Davì G. Platelet activation in obesity and metabolic syndrome. Obes. Rev. 13(1), 27–42 (2012).
   PubMed Web of Science ®Google Scholar
• Whaley-Connell A, McCullough PA, Sowers JR. The role of oxidative stress in the metabolic syndrome. Rev. Cardiovasc. Med. 12(1), 21–29 (2011).
   PubMed Web of Science ®Google Scholar
• Kaneto H, Nakatani Y, Kawamori D et al. Role of oxidative stress, endoplasmic reticulum stress, and c-Jun N-terminal kinase in pancreatic beta-cell dysfunction and insulin resistance. Int. J. Biochem. Cell Biol. 37(8), 1595–1608 (2005).
   PubMed Web of Science ®Google Scholar
• Park S, Yoon SJ, Tae HJ, Shim CY. RAGE and cardiovascular disease. Front. Biosci. 16, 486–497 (2011).
   Web of Science ®Google Scholar
• Rafikov R, Fonseca FV, Kumar S et al. eNOS activation and NO function: structural motifs responsible for the posttranslational control of endothelial nitric oxide synthase activity. J. Endocrinol. 210(3), 271–284 (2011).
   PubMed Web of Science ®Google Scholar
• Förstermann U, Sessa WC. Nitric oxide synthases: regulation and function. Eur. Heart J. 33(7), 829–837, 837a (2012).
   PubMed Web of Science ®Google Scholar
• Horton ES. Effects of lifestyle changes to reduce risks of diabetes and associated cardiovascular risks: results from large-scale efficacy trials. Obesity (Silver Spring) 17(Suppl. 3), S43–S48 (2009).
   PubMed Web of Science ®Google Scholar
• Aucott L, Gray D, Rothnie H, Thapa M, Waweru C. Effects of lifestyle interventions and long-term weight loss on lipid outcomes – a systematic review. Obes. Rev. 12(5), e412–e425 (2011).
   Google Scholar
• Caballero AE. Endothelial dysfunction, inflammation, and insulin resistance: a focus on subjects at risk for type 2 diabetes. Curr. Diab. Rep. 4(4), 237–246 (2004).
   Google Scholar
• Schulz E, Gori T, Münzel T. Oxidative stress and endothelial dysfunction in hypertension. Hypertens. Res. 34(6), 665–673 (2011).
   PubMed Web of Science ®Google Scholar
• Yang Y, Hayden MR, Sowers S, Bagree SV, Sowers JR. Retinal redox stress and remodeling in cardiometabolic syndrome and diabetes. Oxid. Med. Cell. Longev. 3(6), 392–403 (2010).
   Google Scholar
• Janiszewski PM, Ross R. The utility of physical activity in the management of global cardiometabolic risk. Obesity (Silver Spring) 17(Suppl. 3), S3–S14 (2009).
   Google Scholar
• Wilson PW. Evidence of systemic inflammation and estimation of coronary artery disease risk: a population perspective. Am. J. Med. 121(10 Suppl. 1), S15–S20 (2008).
   PubMed Web of Science ®Google Scholar
• Shah A, Mehta N, Reilly MP. Adipose inflammation, insulin resistance, and cardiovascular disease. JPEN. J. Parenter. Enteral Nutr. 32(6), 638–644 (2008).
   PubMed Web of Science ®Google Scholar
• Ohman MK, Wright AP, Wickenheiser KJ, Luo W, Eitzman DT. Visceral adipose tissue and atherosclerosis. Curr. Vasc. Pharmacol. 7(2), 169–179 (2009).
   PubMed Web of Science ®Google Scholar
• Kadoglou NP, Lampropoulos S, Kapelouzou A et al. Serum levels of apelin and ghrelin in patients with acute coronary syndromes and established coronary artery disease–KOZANI STUDY. Transl. Res. 155(5), 238–246 (2010).
   PubMed Web of Science ®Google Scholar
• Kadoglou NP, Sailer N, Kapelouzou A et al. Effects of atorvastatin on apelin, visfatin (nampt), ghrelin and early carotid atherosclerosis in patients with Type 2 diabetes. Acta Diabetol. 49(4), 269–276 (2012).
   PubMed Web of Science ®Google Scholar
• Aucott L, Gray D, Rothnie H, Thapa M, Waweru C. Effects of lifestyle interventions and long-term weight loss on lipid outcomes – a systematic review. Obes. Rev. 12, e412–e425 (2011).
   Google Scholar
• Skilton MR, Chin-Dusting JP, Dart AM et al.; D.E.S.I.R. Study Group. Metabolic health, obesity and 9-year incidence of peripheral arterial disease: the D.E.S.I.R. study. Atherosclerosis 216(2), 471–476 (2011).
   Google Scholar
• Kadoglou NP, Iliadis F, Liapis CD. Exercise and carotid atherosclerosis. Eur. J. Vasc. Endovasc. Surg. 35(3), 264–272 (2008).
   PubMedGoogle Scholar
• Kadoglou NP, Iliadis F, Liapis CD, Perrea D, Angelopoulou N, Alevizos M. Beneficial effects of combined treatment with rosiglitazone and exercise on cardiovascular risk factors in patients with Type 2 diabetes. Diabetes Care 30(9), 2242–2244 (2007).
   PubMed Web of Science ®Google Scholar
• Wilhelmsen L, Svärdsudd K, Eriksson H et al. Factors associated with reaching 90 years of age: a study of men born in 1913 in Gothenburg, Sweden. J. Intern. Med. 269(4), 441–451 (2011).
   PubMed Web of Science ®Google Scholar
• Rolland C, Hession M, Broom I. Effect of weight loss on adipokine levels in obese patients. Diabetes. Metab. Syndr. Obes. 4, 315–323 (2011).
   PubMedGoogle Scholar
• Zoladz JA, Pilc A, Majerczak J, Grandys M, Zapart-Bukowska J, Duda K. Endurance training increases plasma brain-derived neurotrophic factor concentration in young healthy men. J. Physiol. Pharmacol. 59(Suppl. 7), 119–132 (2008).
   PubMed Web of Science ®Google Scholar
• Straznicky NE, Lambert EA, Grima MT et al. The effects of dietary weight loss with or without exercise training on liver enzymes in obese metabolic syndrome subjects. Diabetes. Obes. Metab. 14(2), 139–148 (2012).
   PubMed Web of Science ®Google Scholar
• Swislocki AL, Siegel D, Jialal I. Pharmacotherapy for the metabolic syndrome. Curr. Vasc. Pharmacol. 10(2), 187–205 (2012).
   PubMed Web of Science ®Google Scholar
• Siegel D, Swislocki AL. Hypertensive treatment in patients with metabolic syndrome. Metab. Syndr. Relat. Disord. 8(2), 95–104 (2010).
   Google Scholar
• Christopoulou FD, Kiortsis DN. An overview of the metabolic effects of rimonabant in randomized controlled trials: potential for other cannabinoid 1 receptor blockers in obesity. J. Clin. Pharm. Ther. 36(1), 10–18 (2011).
   PubMed Web of Science ®Google Scholar
• García Díaz E, Martín Folgueras T. Systematic review of the clinical efficacy of sibutramine and orlistat in weigth loss, quality of life and its adverse effects in obese adolescents. Nutr. Hosp. 26(3), 451–457 (2011).
   Google Scholar
• Omboni S, Malacco E, Parati G. Zofenopril plus hydrochlorothiazide fixed combination in the treatment of hypertension and associated clinical conditions. Cardiovasc. Ther. 27(4), 275–288 (2009).
   PubMed Web of Science ®Google Scholar